Table 2 Treatment-emergent adverse events (N = 37).
CTCAE term | All | G1-2 | G3-4 | G5 |
|---|---|---|---|---|
No. (%) | No. (%) | No. (%) | No. (%) | |
Neutrophil count decreased | 17 (45.9) | 1 (2.7) | 16 (43.2) | – |
Lymphocyte count decreased | 17 (45.9) | 8 (21.6) | 9 (24.3) | – |
Infection event | 17 (45.9) | 4 (10.8) | 11 (29.7) | 2 (5.4)a |
Anemia | 16 (43.2) | 13 (35.1) | 3 (8.1) | 0 |
Fever | 16 (43.2) | 13 (35.1) | 3 (8.1) | 0 |
White blood cell decreased | 15 (40.5) | 5 (13.5) | 10 (27) | – |
Platelet count decreased | 12 (32.4) | 4 (10.8) | 8 (21.6) | – |
Lung infection | 12 (32.4) | 3 (8.1) | 9 (24.3) | 0 |
Febrile neutropenia | 11 (29.7) | – | 11 (29.7) | 0 |
Alanine aminotransferase increased | 9 (24.3) | 8 (21.6) | 1 (2.7) | – |
Alkaline phosphatase increased | 9 (24.3) | 8 (21.6) | 1 (2.7) | – |
Cough | 9 (24.3) | 2 (5.4) | 7 (18.9) | – |
Aspartate aminotransferase increased | 8 (21.6) | 5 (13.5) | 3 (8.1) | – |
Gamma-glutamyl transpeptidase increased | 8 (21.6) | 8 (21.6) | 0 | – |
Hypokalemia | 8 (21.6) | 5 (13.5) | 3 (8.1) | 0 |
Fatigue | 8 (21.6) | 8 (21.6) | 0 | – |
Dizziness | 8 (21.6) | 4 (10.8) | 4 (10.8) | – |
Hypocalcemia | 7 (18.9) | 7 (18.9) | 0 | 0 |
Bleeding event | 7 (18.9) | 5 (13.5) | 2 (5.4) | 0 |
Creatinine increased | 5 (13.5) | 2 (5.4) | 3 (8.1) | – |
Diarrhea | 5 (13.5) | 5 (13.5) | 0 | 0 |
Blood bilirubin increased | 4 (10.8) | 4 (10.8) | 0 | – |
Acute kidney injury | 4 (10.8) | – | 4 (10.8) | 0 |
Hyponatremia | 4 (10.8) | 1 (2.7) | 3 (8.1) | 0 |
Headache | 4 (10.8) | 1 (2.7) | 3 (8.1) | – |
Nausea | 4 (10.8) | 4 (10.8) | 0 | – |
Infusion reactions to rituximab | 4 (10.8) | 2 (5.4) | 2 (5.4) | 0 |
Hyperglycemia | 3 (8.1) | 1 (2.7) | 2 (5.4) | 0 |
Vomiting | 3 (8.1) | 3 (8.1) | 0 | 0 |
Atrial fibrillation | 1 (2.7) | 0 | 1 (2.7) | 0 |
